All In Biotech

Drug Trial Radar · NCT01910883

Safety and Tolerability of Single and Multiple Intravenous Doses of Finafloxacin in Healthy Subjects

Finafloxacin - A Double-blind, Placebo-controlled, Randomised, Dose-escalating, Crossover Study to Determine the Safety and Tolerability of Single and Multiple Intravenous Doses of Finafloxacin in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Jul 30, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

58

Actual

Start

Sep 2010

Primary completion

Mar 2012

Study completion Mar 2012

Sponsor

Lead sponsor
MerLion Pharmaceuticals GmbHIndustry
Sponsor type
Industry
First posted
Jul 30, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is the first time finafloxacin was administered to humans intravenously. The principal aim of this study was to obtain safety and tolerability data when finafloxacin was administered intravenously as single and multiple doses to healthy subjects.

Conditions

  • Healthy

Interventions

  • Finafloxacin i.v. solution 200 mgDrug

  • Finafloxacin i.v. solution 400 mgDrug

  • Finafloxacin i.v. solution 600 mgDrug

  • Finafloxacin i.v. solution 800 mgDrug

  • Finafloxacin i.v. solution 1000 mgDrug

  • Placebo i.v. solutionDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SafetyTime frame: 1 to 7 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Covance Clinical Research Unit Ltd

    Leeds, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.